Business Wire

BITEPRO

15.10.2019 16:02:07 CEST | Business Wire | Press release

Share
British Firm BitePRO Claim Education Professionals Are Bitten By Pupils On Daily Basis

According to British firm BitePRO , teachers and education professionals are at increased risk of being bitten by pupils and the consequences can be severe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005707/en/

Human bites can more dangerous than animal bites because of the large quantity and types of bacteria and viruses contained in the human mouth. Human bites that break the skin can become severely infected.

According to several medical sources, human bites have been shown to transmit hepatitis B, hepatitis C, herpes simplex virus (HSV) syphilis, tuberculosis, actinomycosis, tetanus and even the human immunodeficiency virus (HIV).

Robert Kaiser, CEO of BitePRO a firm specialised in bite resistant clothing states: “We are fully aware of teachers working in special educational needs schools or units for pupils with severe mental and behavioural problems who were bitten so hard, so they had to be given vaccinations against infectious diseases and viruses such as Hepatitis B. Many also required immediate surgery.”

“Regrettably, there is still a culture in some schools, particularly where pupils have severe behavioural problems, that being assaulted is all part of the job.”

Recently, teachers seem to talk openly about their daily experiences of being bitten, and their visits to hospitals. This is most certainly the case.

Brett Bigham, Oregon’s Teacher of the Year in 2014 reported to have been bitten so badly that he was sent to the hospital.

In October 2019 a Canberra public school worker was repeatedly bitten by one of her students. She was injured on a weekly basis, for six months, by a child with a mental disability. In an interview with local media she stated: “"I was bitten on the arms; I was bitten on the stomach and I was bitten on the leg. That was day one."

The ‘News and Features from the National Education Association’ admitted or rather stated on the 20 June 2019 that many teachers, administrators, and education support professionals (ESPs) are at risk of being bitten while at work.

Educational professionals around the world are now rightly calling for greater protection from children who bite them. Human teeth breaking their skin and leading to serious injury, infections, long term trauma and require complex surgery cannot be part of their daily routine.

Many have now walked away from a profession they were once extremely passionate about, because medical experts have been able to identify that they suffer from PTSD (Post Traumatic Stress Disorder), an illness, usually associated to soldiers returning from wars, having witnessed severe levels of violence.

According to Robert Kaiser, bite resistant arm guards might not change the behaviour of violent children, or the behaviour of children diagnosed with specific mental illnesses. But there is no question about it, such type of highly protective clothing will reduce the risk of injury and infections. It will prevent immense long-term emotional distress to teachers. It will help them to continue working within a sector they are passionate about.

Kayleigh Davis, Senior Consultant at BitePRO is also keen to point out some vital legal information: “Today’s legal environment will require a risk assessment to be conducted, highlighting any realistic risk employees are being exposed to e.g. being bitten by a pupil.”

“The purpose of such is to very clearly identifying a) the precise risk, b) the potential liability and c) the implementation of effective mitigating measures. I believe that BitePRO should be considered as one of many mitigations measures you can utilise and implement to reduce a realistic risk faced by today’s educational professionals.”

“Failing to do so can ultimately result in liability claims and legal action being taken against your organisation by either an injured employee or indeed an overseeing government body.”

The Portland Tribune reported on 01 February 2019 that eight educational assistants are suing Portland Public Schools and several administrators for $3.6 million alleging the special needs students they were supposed to assist frequently assaulted them by biting and scratching etc. The lawsuit accused the district partly of negligence. The lawsuit claimed the district and administrators did not sufficiently protect the educational assistants or students.

The fact of the matter is a school and any other educational facility is required to provide a safe and healthy workplace: It is not optional. It is the law.

For any product related questions, please email info@bite-pro.com .

### END

About BitePRO:

The BitePRO brand is part of PPSS Group’s global operation. PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. Please follow BitePRO on social media: Facebook , LinkedIn , Twitter and Instagram .

Link:

ClickThru

Social Media:

https://www.facebook.com/biteproclothing/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye